title: Effects of administration of monoclonal antibodies (anti-CD4 or anti-CD8) on the development of autoimmune diseases in (NZW x BXSB)F1 mice.
abstract: (NZW x BXSB)F1 (W/BF1) mice spontaneously develop autoimmune diseases, characterized by lymphadenopathy, lupus nephritis, and immune thrombocytopenia associated with various autoantibodies such as anti-DNA, anti-platelet and anti-cardiolipin antibodies (Abs). In the present study, we investigate the effects of administration of monoclonal Abs (anti-CD4 or anti-CD8 mAb) on the development of autoimmune diseases in W/BF1 mice. MAb was administered from the age of 7 weeks. Prolongation of survival rate and reduction of severity of autoimmune diseases were observed after treatment with anti-CD4 mAb. However, anti-CD8 mAb treatment accelerated the diseases. Serum levels of IFN-gamma and IL-10 in old W/BF1 mice were significantly high, whereas IL-4 levels were low in comparison with those of young W/BF1 mice; the expression of mRNA of IFN-gamma, IL-4 or IL-10 in CD4+ T cells of old W/BF1 mice was parallel to the serum levels of each cytokine. These observations suggest that CD4+ cells are involved in the development of autoimmune diseases in W/BF1 mice, and that CD8+ cells have a suppressive effect on the development of autoimmune diseases in W/BF1 mice.
authors.affiliation: First Department of Pathology, Kansai Medical University, Moriguchi, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Adachi
authors.forename: M
authors.initials: M
authors.lastname: Inaba
authors.forename: A
authors.initials: A
authors.lastname: Sugihara
authors.forename: M
authors.initials: M
authors.lastname: Koshiji
authors.forename: K
authors.initials: K
authors.lastname: Sugiura
authors.forename: Y
authors.initials: Y
authors.lastname: Amoh
authors.forename: S
authors.initials: S
authors.lastname: Mori
authors.forename: T
authors.initials: T
authors.lastname: Kamiya
authors.forename: H
authors.initials: H
authors.lastname: Genba
authors.forename: S
authors.initials: S
authors.lastname: Ikehara
mesh_terms: D000367:Age Factors; D000818:Animals; D000974:Antibodies, Antinuclear / Q000276:immunology / Q000302:isolation & purification; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000276:immunology; D001327:Autoimmune Diseases / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000378:metabolism; D007371:Interferon-gamma / Q000097:blood / Q000235:genetics; D016753:Interleukin-10 / Q000097:blood / Q000235:genetics; D007376:Interleukin-2 / Q000235:genetics / Q000276:immunology; D015847:Interleukin-4 / Q000097:blood / Q000235:genetics; D007678:Kidney Glomerulus / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008814:Mice, Inbred NZB; D010641:Phenotype; D010976:Platelet Count; D011507:Proteinuria / Q000150:complications
chemical_list: D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal; D007376:Interleukin-2; D016753:Interleukin-10; D015847:Interleukin-4; D007371:Interferon-gamma